AG
MRSN

Algert Global’s Mersana Therapeutics MRSN Stock Holding History

Algert Global’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-4,053
Closed -$30K – 1269
2025
Q2 		$30K Sell
4,053
-1,348
-25% -$11.8K ﹤0.01% 1167
2025
Q1 		$46.5K Buy
5,401
+2,998
+125% +$46.3K ﹤0.01% 1154
2024
Q4 		$85.9K Sell
2,403
-136
-5% -$7.04K ﹤0.01% 1128
2024
Q3 		$120K Buy
2,539
+753
+42% +$33.2K ﹤0.01% 1100
2024
Q2 		$89.8K Buy
+1,786
New +$129K ﹤0.01% 1401
2023
Q3 		– Sell
-8,794
Closed -$723K – 1203
2023
Q2 		$723K Buy
8,794
+7,540
+601% +$1.1M 0.03% 729
2023
Q1 		$129K Sell
1,254
-1,092
-47% -$153K 0.01% 1069
2022
Q4 		$344K Hold
2,346
– – 0.02% 905
2022
Q3 		$397K Buy
+2,346
New +$381K 0.02% 873
2022
Q1 		– Sell
-1,004
Closed -$156K – 1263
2021
Q4 		$156K Buy
1,004
+288
+40% +$56K 0.02% 885
2021
Q3 		$169K Buy
+716
New +$209K 0.02% 935
2021
Q1 		– Sell
-372
Closed -$248K – 494
2020
Q4 		$248K Buy
+372
New +$207K 0.07% 324
2020
Q3 		– Sell
-1,362
Closed -$797K – 455
2020
Q2 		$797K Sell
1,362
-313
-19% -$107K 0.27% 134
2020
Q1 		$244K Sell
1,675
-406
-20% -$70.9K 0.1% 281
2019
Q4 		$298K Buy
2,081
+532
+34% +$38.9K 0.09% 265
2019
Q3 		$61K Hold
1,549
– – 0.02% 339
2019
Q2 		$157K Buy
1,549
+712
+85% +$83.9K 0.06% 299
2019
Q1 		$110K Buy
+837
New +$105K 0.06% 276

Other funds holding MRSN

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
AV
Alamea Verwaltungs Edison, New Jersey $125M AUM 27.56% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Algert Global's MRSN Position: Q3 2025 in Review

Algert Global sold out of Mersana Therapeutics (MRSN) in Q3 2025, closing a stake of 4,053 shares — an estimated $30K sold.

Algert Global first reported a position in MRSN in Q1 2019 and held it in 18 quarters. The position peaked at $797K in Q2 2020. 49 funds tracked by Wall St. Rank hold MRSN as of Q3 2025.

  • Algert Global reported no remaining Mersana Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Algert Global sold 4,053 Mersana Therapeutics shares in Q3 2025, an estimated $30K.
  • Algert Global first reported a position in Mersana Therapeutics in Q1 2019 and held it in 18 quarters.
  • Algert Global's Mersana Therapeutics position peaked at $797K in Q2 2020.
  • 49 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q3 2025.

Based on Algert Global's 13F filing for Q3 2025, filed 14 Nov 2025.